How should tranexamic acid be dosed for an adult with acute upper gastrointestinal bleeding, and what are its contraindications?

Tranexamic Acid Should NOT Be Used for Upper Gastrointestinal Bleeding

Based on the highest quality evidence, tranexamic acid is not recommended for acute upper gastrointestinal bleeding (UGIB) and should not be administered in this setting. The landmark HALT-IT trial conclusively demonstrated that tranexamic acid does not reduce mortality from gastrointestinal bleeding and may increase thromboembolic complications 1.

Why TXA Fails in UGIB

The 2024 French guidelines explicitly state that in cases of upper gastrointestinal hemorrhage, the HALT-IT study concluded that tranexamic acid was ineffective whether or not an anticoagulant was present 1. This represents a critical distinction from trauma-related bleeding, where TXA has proven mortality benefits.

The HALT-IT trial (2020), the largest and most definitive study with 12,009 patients, found:

• No reduction in death from bleeding: 4% in both TXA and placebo groups (RR 0.99,95% CI 0.82-1.18) 2
• Increased venous thromboembolism: 0.8% vs 0.4% (RR 1.85,95% CI 1.15-2.98) 2
• Increased seizure risk: RR 1.73 (95% CI 1.03-2.93) 3, 4

The Evidence Landscape

Multiple systematic reviews from 2021-2026 consistently confirm these findings:

• A 2022 meta-analysis found high-dose IV TXA does not improve mortality or bleeding outcomes and increases adverse events 3
• A 2024 systematic review concluded TXA does not reduce mortality and may confer increased seizure risk 4
• A 2026 overview of reviews (34,351 patients) states current high-quality evidence does not support routine TXA use for mortality reduction in UGIB 5

Why TXA Works in Trauma But Not UGIB

The pathophysiology differs fundamentally:

Trauma bleeding (where TXA is effective 6):

• Hyperfibrinolysis is a primary driver
• Early administration (within 3 hours) prevents fibrinolytic coagulopathy
• Standard dosing: 1g bolus over 10 minutes, then 1g over 8 hours 6, 7

UGIB (where TXA fails):

• Bleeding is primarily anatomical/vascular, not fibrinolytic
• Endoscopic hemostasis is the definitive treatment
• Antifibrinolytic therapy does not address the underlying lesion

Clinical Recommendation Algorithm

For acute UGIB:

1. Do NOT administer tranexamic acid - it provides no mortality benefit and increases thrombotic risk
2. Focus on proven interventions:
   • High-dose PPI therapy (IV bolus followed by continuous infusion for 3 days) 8
   • Urgent endoscopy within 24 hours 8
   • Blood transfusion if Hgb <80 g/L (higher threshold with cardiovascular disease) 8
   • Thermocoagulation, sclerosant injection, or clips for high-risk stigmata 8

Exception - If patient is on anticoagulants:

• TXA still follows the same indication as non-anticoagulated patients (i.e., NOT indicated for UGIB) 1
• Focus on anticoagulant reversal and endoscopic intervention instead

Contraindications from FDA Label

Even if considering TXA, it is contraindicated in 9:

• Active intravascular clotting
• Subarachnoid hemorrhage (risk of cerebral edema/infarction)
• Hypersensitivity to tranexamic acid

Critical safety warning: TXA is for intravenous use only - inadvertent intrathecal administration causes seizures and cardiac arrhythmias 9.

Common Pitfall to Avoid

Do not extrapolate trauma data to UGIB. The CRASH-2 trial's success in trauma has led to inappropriate generalization. The 2019 International Consensus Group guidelines for nonvariceal UGIB make no recommendation for TXA use, implicitly acknowledging lack of efficacy 8.

The 2022 Indonesian national consensus explicitly advises against routine TXA use in UGIB 5, aligning with current best evidence.